

TITLE PAGE

Title: Contemporary Approach to the Diagnosis of Malignant Pleural Effusion

Running Head: Diagnosis of Malignant Pleural Effusion

Author names and affiliations:

Viren Kaul, MD

ORCID iD: 0000-0003-3047-4840

Division of Pulmonary and Critical Care Medicine

Elmhurst Hospital Center, Icahn School of Medicine at Mount Sinai, Elmhurst, NY, USA

David J. McCracken, MRCP

Clinical Pleural Fellow

Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford, UK

Oxford Respiratory Trials Unit, Oxford, UK

Najib M. Rahman, DPhil, MSc, FRCP

Professor of Respiratory Medicine

Director, Oxford Respiratory Trials Unit, Nuffield Department of Medicine, University of Oxford

Consultant Respiratory Physician, Lead for Pleural Diseases, Oxford Centre for Respiratory Medicine

Tutor in Clinical Medicine, University College, Oxford, UK

Oleg Epelbaum, MD, ATSF

ORCID iD: 0000-0002-6920-0540

Director, Pleural Disease Service

Division of Pulmonary, Critical Care and Sleep Medicine, Westchester Medical Center

Associate Professor of Clinical Medicine, New York Medical College, Valhalla, NY, USA

Corresponding author: Viren Kaul. Email: jishuviren@gmail.com. Address: 7901 Broadway, Elmhurst, NY 11373.

Source(s) of support in the form of equipment, drugs, or grants (including grant numbers): None

Keywords: malignant pleural effusion, diagnosis, approach

Word count: 3715, **Figures:** 4, **Tables:** 1, **Video:** 1. This article has an online supplement, which is accessible from this issue's table of contents online at www.atsjournals.org

ABSTRACT

Advanced malignancy is a prevalent cause of exudative pleural effusion. The management of malignant pleural effusion (MPE) has been the subject of several recent randomized controlled trials and excellent reviews. Less attention has been focused on another controversial and challenging aspect of MPE: establishing the diagnosis. Prior to selecting the optimal management strategy, the presence of an MPE must first be correctly identified with an emphasis on minimizing invasiveness and discomfort in a patient afflicted with late-stage cancer. The aim of the present review is to summarize the current knowledge about MPE diagnostics and to propose an algorithm for the diagnosis of MPE in established or suspected malignancy.

71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92

INTRODUCTION

93

94 Malignancy is the second most common etiology of exudative pleural effusions (1), leading to
95 over 125,000 admissions in the United States in 2012 with a median cost per hospitalization of
96 more than \$42,000 (2). Lung and breast cancer together account for the majority of primary
97 tumors metastatic to the pleural space (3). Malignant pleural effusion (MPE) signifies an
98 advanced stage of malignancy, so unsurprisingly the median survival in cases of lung and breast
99 carcinoma ranges from approximately 2 to 6 months (4). The identification of an MPE may have
100 implications for the staging, management, and prognosis of a patient with established cancer, or
101 it can be the source of initial diagnostic material. A pleural effusion can be definitively called
102 MPE only after the detection of neoplastic cells or tissue in the pleural space. This is important
103 as other types of pleural effusions could occur during a cancer patient’s clinical course. So-called
104 “paramalignant effusions,” may result from complications of cancer such as endobronchial
105 obstruction or pulmonary embolism but do not represent direct involvement of the pleural space
106 by malignancy. What follows is a narrative review of the contemporary understanding of MPE
107 diagnostics. Table 1 summarizes the performance characteristics of these various diagnostic
108 modalities, which are synthesized into a proposed algorithm in Figure 1.

109

110

111 **CLINICAL AND RADIOLOGICAL EVALUATION**

112

113 **Clinical Features**

114

The majority of patients with MPE are symptomatic at presentation, typically reporting subacute dyspnea and chest discomfort (5)(6). Ferrer et al (7) studied the following 5 features of 93 patients referred for thoracoscopy and determined that all patients fulfilling ≥ 4 criteria were eventually diagnosed with MPE, whereas those with one or none of these characteristics invariably had benign effusions:

- a) Clinical symptoms (dyspnea, chest pain, constitutional symptoms)
- b) Symptomatic period >1 month
- c) Absence of fever
- d) Blood-tinged pleural effusion
- e) Chest CT suggestive of malignancy (mass, atelectasis, adenopathy)

Chest Radiography and Computed Tomography

On plain chest radiographs, MPE is usually unilateral, though bilateral effusions are present in about 11% of cases (8). Over half of MPE are large, occupying more than two-thirds of a hemithorax, or massive (i.e., complete opacification) (9). Contrast-enhanced chest CT can contribute valuable predictive information in cases of suspected pleural malignancy. Nodular pleural thickening, mediastinal pleural thickening, parietal pleural thickening >1 cm, and circumferential pleural thickening are all highly specific (88-100%) for malignant involvement (10). Porcel et al used a single-center sample to derive a scoring system for identifying malignancy based on chest CT findings that included the following elements and point values (11):

137

138 a. Pleural lesion ≥ 1 cm (5 points)

139 b. Presence of liver metastasis, abdominal mass or lung mass/nodule (3 points each)

140 c. Absence of pleural loculations, pericardial effusion, or cardiomegaly (2 points each)

141

142 A total score of ≥ 7 points predicted MPE with a sensitivity of 88% and a specificity of 94% in the
143 validation cohort. These encouraging performance characteristics were, however, not replicated
144 when two UK centers correlated radiologists' CT interpretations with subsequent pleural
145 histology (12). In clinical practice, it turned out that the sensitivity and specificity of CT reports
146 for pleural malignancy were 68% and 78%, respectively. These results translated to a negative
147 predictive value of 65%, meaning that one in three patients with MPE would have been missed
148 based on the CT reading. While informative if present, CT features of malignancy cannot by
149 themselves substitute for cytohistological sampling nor should their absence preclude additional
150 evaluation in real-world practice.

151

152 **Magnetic Resonance Imaging**

153

154 Using signal intensity as the criterion, magnetic resonance imaging (MRI) performs comparably
155 to CT in the radiological differentiation of benign from malignant pleural disease, though it is less
156 widely available and more challenging to obtain (13). It may have particular value in delineating
157 the presence or absence of invasion in mesothelioma cases, but it currently lacks a defined role
158 in the initial evaluation of suspected pleural malignancy (14).

Positron Emission Tomography

¹⁸Fluorodeoxyglucose positron emission tomography (¹⁸FDG-PET) is a functional imaging technique used widely in the field of oncology for characterization of suspected malignancy and in the search for metastases. The avidity of the pleura for ¹⁸FDG can be quantified using the maximum standardized uptake value (SUV_{max}) or assessed qualitatively by comparison with normal background activity (Figure 2). The integration of ¹⁸FDG-PET with chest CT (PET/CT) raised the sensitivity of CT findings alone from 70% to 93% in a study of 86 patients with metastatic pleural malignancy (15). In this study performed in an endemic area for tuberculosis (TB), the specificity of PET by itself for MPE was limited to 63% primarily by falsely positive TB pleuritis cases. Integrated PET/CT imaging compensated for this shortcoming by allowing concurrent functional and anatomical evaluation of the pleural space with a resultant specificity increase to 93%. The addition of PET did not increase the already very high (>90%) sensitivity and specificity of CT scanning for the identification of pleural mesothelioma. Meta-analysis of 14 publications through the year 2012 yielded a best-case specificity of ¹⁸FDG-PET of only 76%, which was reached by pooling just those studies that applied qualitative criteria for ¹⁸FDG avidity (16). Of note, a study from an area of low TB prevalence included in this meta-analysis reported a specificity of only 35% for PET/CT despite a population enriched with cases of mesothelioma (17). Many of the false positive studies occurred in patients status post talc pleurodesis. False positivity has thus consistently been the Achilles heel of ¹⁸FDG-PET, which severely limits the utility of a test applied to cases of suspected pleural malignancy. Much like CT and other forms of imaging,

¹⁸FDG-PET cannot differentiate benign from malignant pleuritis with sufficient accuracy to obviate cytohistology.

In summary, scoring systems and advanced radiological techniques can heighten suspicion for malignant pleural disease. However, given that tissue confirmation is required for definitive diagnosis, clinical features and radiology should be regarded as a triage strategy rather than conclusive evidence of MPE.

PLEURAL FLUID ANALYSIS

Biochemistry

Ultrasound-guided thoracentesis is the initial procedure of choice for the investigation of suspected MPE. Routine pleural fluid (PF) analysis in MPE will typically reveal exudative characteristics with a predominance of mononuclear cells. The differential diagnosis of this laboratory pattern primarily includes TB, collagen vascular disease, and late effusions complicating coronary artery bypass graft surgery. In endemic countries, TB pleuritis poses the biggest diagnostic challenge and is the only one of the aforementioned etiologies that frequently occurs without historical clues. PF adenosine deaminase (ADA) level can help distinguish TB from MPE as it is characteristically much higher in the former (median 86 U/L) than in the latter (median 23U/L) (18). The so-called “cancer ratio,” defined as serum lactate dehydrogenase/pleural ADA,

at a value >20 has been shown to identify MPE with a sensitivity of 98% and specificity of 94% (19). While not diagnostic, PF pH <7.30, found in about one-third of patients with MPE, is associated with greater PF cytology yield, reduced pleurodesis success, and shorter survival (20). Care must be taken when interpreting low pleural fluid pH values to exclude the possibility of artifact as may occur with an admixture of heparin or lidocaine (21).

Cytology

The diagnosis of MPE by PF sampling can be considered definitive only if cytology shows malignant cells. From their contemporary series of over 3,000 PF aspirations, Porcel et al calculated the yield of the initial PF cytology specimen in MPE to be 51%, which rose to only 59% even after counting second and third cytology specimens in the overall MPE patient sample (N=831) (3). On its surface, the modest 8% incremental yield appears to negate the utility of performing serial PF cytology testing. Viewed another way, however, of the 214 patients with negative first cytology who underwent a second PF aspiration, 55 additional MPE were diagnosed, corresponding to 26% of that group. Further, 52 patients with two negative cytologies underwent a third thoracentesis, and 12 (23%) of these were diagnostic. In agreement with previous work (22), cytological yield in the study by Porcel et al varied greatly with the primary cell type. More exfoliative cell types such as lung adenocarcinoma and ovarian cancer produced yields in excess of 70%, whereas only 25% of lung squamous cell carcinoma cases were diagnosed by PF cytology.

Even lower utility of serial PF cytology emerged from prospectively collected data on 515 patients with MPE wherein the overall yield was 46% (23). Repeat samples were positive in 6 out of 106 initially negative cases (5.6%) and in none of 30 cases that proceeded to a third collection. Expectedly, PF cytology yields varied dramatically by cell type: 95% in ovarian primaries, 82% in pulmonary adenocarcinoma, and 14% in squamous cell cancer of the lung.

Submitting large PF aliquots (i.e., >250cc) does not appear to increase the cytological yield for diagnosis of malignancy (24). The overall detection rate reaches a plateau at a volume of 75cc (25), but at least 150cc may be required to maximize the utility of the cell block preparation (26). Higher volumes may be of incremental value when extensive immunohistochemical testing or molecular genetic analysis of the fluid is anticipated. Malignant PF usually provides sufficient material for genetic profiling of lung cancer, and for this purpose the cell block preparation can substitute for tissue biopsy with a high but imperfect accuracy of about 80% (27).

Tumor Markers

PF tumor markers have been studied individually and in combination as a tool for MPE diagnosis when cytology is negative with the understanding, of course, that they cannot provide pathological material. It has been argued that, for distinguishing MPE from benign effusions in clinical practice, the threshold for positivity of a given tumor marker ought to correspond to the level of 100% specificity in order to preclude false positivity (28). A panel of 4 tumor markers, including familiar ones such as carcinoembryonic antigen (CEA) and cancer antigen (CA)-125,

identified 23% of cytology-negative effusions eventually proven to be malignant (29). Porcel et al have shown that elevation of either CEA or CA 15-3 correctly predicts malignancy in 41% of false negative PF cytology cases (30). When the results are stratified by cell type, it emerges that these tumor markers have similar sensitivity to PF cytology (approximately 70-80%) in exfoliative malignancies such as lung adenocarcinoma and ovarian cancer, limiting their incremental benefit in such cases. However, in less exfoliative lung squamous cell carcinoma, these tumor markers had a sensitivity of 47%, which exceeds the aforementioned sensitivities of PF cytology when this is the primary tumor. In mesothelioma, another malignancy with low cytological yield, the PF tumor marker mesothelin significantly outperformed PF cytology with sensitivity of 71% versus 35% when studied prospectively, though there were false positive results (specificity 89%) (31). Vascular endothelial growth factor (VEGF) is not a tumor marker but rather a potent mediator of pleural fluid formation in MPE. The level of VEGF in PF correlates inversely with survival in non-small cell lung cancer complicated by MPE (32). As a diagnostic tool, using a PF concentration above 652pg/ml as the threshold value, VEGF elevation correctly identified 12 of 20 (60%) cytologically negative MPE confirmed by thoracoscopy (33). False positives did occur at this cut-off, however, translating to a specificity of 83%. Overall, PF tumor markers can support a malignant etiology if elevated, but they are insufficient in isolation for a confident diagnosis of MPE, especially with regard to planning oncological treatment decisions.

PLEURAL BIOPSY

Needle Biopsy

In contrast to TB pleuritis, in which the pleura is typically diffusely involved by granulomatous inflammation, metastatic malignancy tends to implant on the pleura in a patchy distribution. This difference explains the traditionally high yield of “blind” closed needle biopsy of the pleura in TB and its low yield in MPE. In fact, this type of needle biopsy detected fewer cases of malignancy (43%) than did PF cytology (58%) among 281 patients with MPE, and histology diagnosed only an additional 7% of cases missed by cytology (34). Superior sensitivity of PF cytology over “blind” needle histology in MPE (71% vs. 45%) was also demonstrated by another study (35), wherein biopsy diagnosed only 3 cases with negative cytology. In mesothelioma, the utility of this technique varies widely with reported yields ranging from as low as 16% (36) to as high as 44% (37) compared to less variable but still poor results from PF cytology: 30-35% (31,38). Generally, given the challenges posed by small specimens, acquisition of larger tissue biopsies is preferred for the diagnosis of mesothelioma when thoracoscopic sampling is feasible.

Bedside ultrasonography is available to the respiratory clinician and can increase the yield of needle biopsy in MPE by directing the sampling to areas with overt or more probable malignant involvement, such as the basal pleura (Figure 3, Supplemental Video). Sonographically visible pleural thickening >1cm and pleural nodularity are both highly specific—95% and 100%, respectively—for malignancy (39). Koegelenberg et al performed thoracentesis followed by US-directed pleural biopsies in 100 patients with previously undiagnosed exudates (40). Subjects with a sonographically detected pleural mass lesion (N=11) underwent fine needle aspiration,

which was followed by cutting needle biopsy if the on-site aspirate result was anything but lung cancer. Those with pleural thickening visible on US (N=24) underwent cutting needle biopsy if the thickening was ≥ 2.5 cm and closed needle biopsy if it was < 2.5 cm. In the absence of sonographic pleural abnormalities (N=65), US-assisted random closed needle biopsies aiming at the low supradiaphragmatic pleura were performed. With this approach, these investigators achieved an overall diagnostic yield for malignancy of 89.7%, a significant improvement over the 31% yield of PF cytology in the same patients. The authors reported only three minor complications, all after closed needle biopsy.

Dynamic CT guidance for needle biopsies of thickened or nodular pleura is usually the domain of radiologists and is not a bedside modality. Its use nearly doubled the sensitivity of “blind” needle biopsy in one study, which was 44% without imaging and 87% with imaging (41). Static CT imaging, on the other hand, can help respiratory clinicians to identify the optimal needle insertion site. When compared to US-assisted (i.e., non-real-time) cutting needle biopsy in a study that included 93 patients with pleural malignancy, CT-assisted closed needle biopsy produced superior sensitivity: 77% vs. 61% (42). Both techniques performed better in the setting of pleural thickening > 1 cm. Complications were few and minor, comparable between the two procedures. Extrapolating the findings of another group, it is conceivable that the sensitivity gap between CT and US could have been narrowed if real-time US guidance had been used instead of a static technique (43).

Medical thoracoscopy

313

314 Medical thoracoscopy (MT) refers to the insertion of a rigid or semi-rigid thoracoscope into the
315 pleural space of a patient placed in a lateral decubitus position and administered a local
316 anesthetic with or without intravenous sedation. This is in contrast to the general anesthesia
317 and single-lung ventilation that characterize surgical thoracoscopy (see below). The procedure
318 allows direct visualization of the pleural space and the performance of forceps biopsies of
319 abnormal sites on the parietal pleura (Figure 4). Because of the obligatory induction of a
320 pneumothorax, a pleural drain is typically left in place at the conclusion of MT. On the other hand,
321 since the visceral pleura is not traversed, the duration of post-procedure pleural drainage could
322 be brief enough to perform MT as an ambulatory case (44). Not every patient with pleural
323 effusion is capable of undergoing this procedure, particularly among the often-debilitated cohort
324 with MPE. Absolute contraindications include lung extensively adherent to the chest wall
325 prohibiting entry into the pleural space and resting hypercapnia, which is likely to worsen during
326 and after the procedure (45). When Rahman et al aggregated data available prior to 2010 from
327 all series reporting the yield of MT in MPE, the pooled sensitivity was 93% (46). Studies published
328 subsequently have corroborated the >90% diagnostic yield of medical thoracoscopic biopsy in
329 pleural malignancy (47), irrespective of whether biopsies are performed through a rigid or semi-
330 rigid instrument (48). Sensitivity approaching 100% has likewise been reported for MT in
331 mesothelioma (49). Comparison of MT to CT-assisted closed needle biopsy in a randomized
332 controlled trial showed numerical but not statistical superiority of the former for diagnosing
333 malignant pleural disease: sensitivity of 95% vs. 87%, respectively(50). Nor did statistically
334 significant differences emerge in subgroup analysis based on primary site. In appropriate

candidates, MT is a well-tolerated procedure with a favorable risk profile. In the literature survey by Rahman et al, diagnostic MT was found to have no associated mortality. More recently, exceptional MT-related fatalities have appeared in print (47). Overall complication rates are low: 1.6% for major events such as empyema or hemorrhage and 7.3% for minor events such as subcutaneous emphysema or skin infection (46).

Surgical thoracoscopy

The “gold standard” for diagnosing pleural malignancy, but also the most invasive means of doing so, remains surgical pleural biopsy, nowadays increasingly performed thoracoscopically via video assisted thoroscopic surgery. Patients considered for this approach must be capable of tolerating general anesthesia and single lung ventilation, but unlike MT, they are not expected to sustain spontaneous respiration in the face of a partial unilateral pneumothorax. The other traditional differentiating factors between VATS and MT include the performing provider (surgeon vs. pulmonologist), setting and type of anesthesia used, as well as post-operative management (duration of chest tube requirement and pain control). The yield of VATS in MPE ranges from 89-95% with a reported major complication rate of 15-26% in this patient population in older literature (51,52). Recently published retrospective data indicate comparably low major complication rates after both VATS (4.0%) and MT (2.6%) but a significant difference in hospital stay and cost favoring the latter (53). The post-operative pain associated with VATS is less severe than that after thoracotomy, but it can nevertheless be persistent (54).

THE UNDIAGNOSED EFFUSION

Approximately 15-30% of cytology-negative exudative pleural effusions in an unselected population remain without a definable etiology despite histological sampling and are labeled as “non-specific pleuritis” (55,56). In patients with active malignancy, the frequency of “non-specific pleuritis” histology after thoracoscopy has been reported to be as high as 52%, but the majority of these cases could be assigned a clinical correlation such as chemotherapy-induced pleuritis or radiation-induced pleuritis (57). Pleural malignancy is discovered during subsequent surveillance in a small but tangible minority of “non-specific pleuritis” cases (3-12%), thus justifying continued clinical vigilance (56–58).

FUTURE DIRECTIONS

Biomarkers

The current movement towards personalized medicine includes development of biomarkers as diagnostic and monitoring tools. This trend has extended to potential biomarkers of malignancy, among them circulating tumor DNA (ctDNA). The entry of ctDNA into the bloodstream is presumed to occur by way of tumor necrosis or apoptosis, and it is anticipated that its detection may lead to the future development of a so-called “liquid biopsy” (58). The role of ctDNA has

been investigated in breast, colon and most recently in non-small cell lung cancer (59–61). The TRACERx study has demonstrated the utility of this assay for the detection of early stage lung cancer and of disease recurrence (59). Although mutation analysis using ctDNA may already be in use to direct treatment in certain tumors, diagnostic sensitivity, particularly in relation to intrathoracic malignancies, has been limited so far (59,62). Eventually, ctDNA may therefore become a helpful blood-based adjunct in the evaluation of a patient with an undiagnosed exudative pleural effusion. It is doubtful, however, that its use would preclude invasive sampling in cases of suspected pleural malignancy. Notably, the definition of a “liquid biopsy” could be extended to PF such that soluble tumor-derived biomarkers may be part of the future of MPE diagnostics. As an example, a novel technique to identify circulating tumor cells has shown encouraging early results when applied to malignant PF of lung cancer patients (63). The PROMISE study is further cause for optimism with respect to PF biomarkers in MPE (64). Utilizing datasets from five randomized controlled trials, researchers were able to identify four potential PF biomarkers predictive of survival. In the future, it may be possible to apply similar investigative techniques in pursuit of potential diagnostic biomarkers.

Imaging

The utility of PET/CT in malignant pleural disease remains uncertain. The TARGET trial (ISRCTN14024829) has been designed to investigate the role of PET/CT in suspected MPE by assessing whether targeted biopsy based on ¹⁸FDG avidity improves diagnostic sensitivity over conventional CT-guided biopsy with the potential secondary benefit of identifying distant

metastatic disease. This trial also aims to further clarify the role of serum mesothelin by including this biomarker in the assessment of subjects with mesothelioma (65).

Narrow band imaging (NBM) is an endoscopic technique that generates two narrow bands of light to enhance the imaging of blood vessels. The detection of irregular vascular patterns is thought to identify the presence of malignant involvement, thus improving selection of biopsy sites and thereby diagnostic yield. Its use has become an established component in the investigation of head and neck, gastrointestinal, urological and some bronchogenic carcinomas (66). One study has suggested a potential role for NBM during thoracoscopy for suspected malignancy. This approach requires further validation (67).

Thoracic US has become an indispensable tool in pleural disease management due to the high diagnostic sensitivity and improved safety profile when used to facilitate pleural interventions (68). Awaiting confirmation are findings from small-scale feasibility studies indicating that contrast-enhanced US may increase diagnostic accuracy when sampling sub-pleural lesions and may also help to direct pleural biopsy.

CONCLUSION

The diagnosis of MPE can remain elusive after analysis of a single or even multiple PF cytology specimens, especially in relatively non-exfoliative cancer histology. Imaging characteristics and

elevation of PF tumor markers can support ongoing suspicion for MPE despite negative cytology, but both lack the ability to provide pathological material for determination of cell type and molecular genetic profile. The role of serum biomarkers is still at the investigational stage, and they are subject to the same limitations. Depending on availability and the presence or absence of pleural thickening, persistent concern for MPE despite negative PF cytology should prompt imaging-guided needle biopsy of the pleura or MT as the next step, the latter also affording an avenue for therapeutic intervention. In most settings, thoracoscopy is preferable to needle biopsy in suspected mesothelioma. Currently under investigation is the use of PET/CT targeting to improve the utility of needle biopsy in mesothelioma. In appropriate candidates for general anesthesia and single-lung ventilation, surgical thoracoscopy can follow negative PF cytology in centers with limited access to less invasive techniques.

ACKNOWLEDGEMENTS: None

REFERENCES:

1. Feller-Kopman D, Light R. Pleural Disease. *N Engl J Med*. 2018 03;378(18):1754.
2. Taghizadeh N, Fortin M, Shieh B, Tremblay A. Prevalence and Etiology of Pleural Effusions in Hospitalized Patients: An Analysis of HCUP-NIS 2012. *Chest*. 2017 Oct 1;152(4, Supplement):A519.
3. Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. *Arch Bronconeumol*. 2014 May;50(5):161–5.

- 446 4. Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al.
447 Predicting survival in malignant pleural effusion: development and validation of the LENT
448 prognostic score. *Thorax*. 2014 Dec;69(12):1098–104.
- 449 5. Chernow B, Sahn SA. Carcinomatous involvement of the pleura: An analysis of 96 patients.
450 *Am J Med*. 1977 Nov 1;63(5):695–702.
- 451 6. Marel M, Štastný B, Melinová L, Svandová E, Light RW. Diagnosis of Pleural Effusions:
452 Experience With Clinical Studies, 1986 to 1990. *Chest*. 1995 Jun 1;107(6):1598–603.
- 453 7. Ferrer J, Roldán J, Teixidor J, Pallisa E, Gich I, Morell F. Predictors of pleural malignancy
454 in patients with pleural effusion undergoing thoracoscopy. *Chest*. 2005 Mar;127(3):1017–
455 22.
- 456 8. Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of
457 lung cancer patients with pleural effusions. *Respirology*. 2015 May;20(4):654–9.
- 458 9. Porcel JM, Vives M. Etiology and pleural fluid characteristics of large and massive
459 effusions. *Chest*. 2003 Sep;124(3):978–83.
- 460 10. Leung AN, Müller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease.
461 *Am J Roentgenol*. 1990 Mar;154(3):487–92.
- 462 11. Porcel JM, Pardina M, Bielsa S, González A, Light RW. Derivation and validation of a CT
463 scan scoring system for discriminating malignant from benign pleural effusions. *Chest*.
464 2015 Feb;147(2):513–9.
- 465 12. Hallifax RJ, Haris M, Corcoran JP, Leyakathalikhhan S, Brown E, Srikantharaja D, et al.
466 Role of CT in assessing pleural malignancy prior to thoracoscopy. *Thorax*. 2015
467 Feb;70(2):192–3.
- 468 13. Falaschi F, Battolla L, Mascalchi M, Cioni R, Zampa V, Lencioni R, et al. Usefulness of
469 MR signal intensity in distinguishing benign from malignant pleural disease. *Am J*
470 *Roentgenol*. 1996 Apr;166(4):963–8.
- 471 14. Truong MT, Viswanathan C, Godoy MBC, Carter BW, Marom EM. Malignant pleural
472 mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment
473 considerations. *Semin Roentgenol*. 2013 Oct;48(4):323–34.
- 474 15. Sun Y, Yu H, Ma J, Lu P. The Role of 18F-FDG PET/CT Integrated Imaging in
475 Distinguishing Malignant from Benign Pleural Effusion. *PloS One*. 2016;11(8):e0161764.
- 476 16. Porcel JM, Hernández P, Martínez-Alonso M, Bielsa S, Salud A. Accuracy of
477 fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural
478 effusions: a meta-analysis. *Chest*. 2015 Feb;147(2):502–12.

- 479 17. Coolen J, De Keyzer F, Naftoux P, De Wever W, Doods C, Vansteenkiste J, et al.
480 Malignant Pleural Disease: Diagnosis by Using Diffusion-weighted and Dynamic Contrast-
481 enhanced MR Imaging—Initial Experience. *Radiology*. 2012 Jun 1;263(3):884–92.
- 482 18. Valdés L, San-José E, Ferreiro L, Golpe A, González-Barcala F-J, Toubes ME, et al.
483 Predicting malignant and tuberculous pleural effusions through demographics and pleural
484 fluid analysis of patients. *Clin Respir J*. 2015 Apr;9(2):203–13.
- 485 19. Verma A, Abisheganaden J, Light RW. Identifying Malignant Pleural Effusion by A Cancer
486 Ratio (Serum LDH: Pleural Fluid ADA Ratio). *Lung*. 2016 Feb;194(1):147–53.
- 487 20. Sahn SA, Good JT. Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and
488 therapeutic implications. *Ann Intern Med*. 1988 Mar;108(3):345–9.
- 489 21. Rahman NM, Mishra EK, Davies HE, Davies RJO, Lee YCG. Clinically Important Factors
490 Influencing the Diagnostic Measurement of Pleural Fluid pH and Glucose. *Am J Respir Crit*
491 *Care Med*. 2008 Sep 1;178(5):483–90.
- 492 22. Naylor B, Schmidt RW. The case for exfoliative cytology of serous effusions. *Lancet*. 1964
493 Mar 28;1(7335):711–2.
- 494 23. Arnold DT, De Fonseca D, Perry S, Morley A, Harvey JE, Medford A, et al. Investigating
495 unilateral pleural effusions: the role of cytology. *Eur Respir J*. 2018 Nov;52(5).
- 496 24. Abouzgheib W, Bartter T, Dagher H, Pratter M, Klump W. A prospective study of the
497 volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. *Chest*.
498 2009 Apr;135(4):999–1001.
- 499 25. Rooper LM, Ali SZ, Olson MT. A minimum fluid volume of 75 mL is needed to ensure
500 adequacy in a pleural effusion: a retrospective analysis of 2540 cases. *Cancer Cytopathol*.
501 2014 Sep;122(9):657–65.
- 502 26. Swiderek J, Morcos S, Donthireddy V, Surapaneni R, Jackson-Thompson V, Schultz L, et
503 al. Prospective study to determine the volume of pleural fluid required to diagnose
504 malignancy. *Chest*. 2010 Jan;137(1):68–73.
- 505 27. Liu X, Lu Y, Zhu G, Lei Y, Zheng L, Qin H, et al. The diagnostic accuracy of pleural
506 effusion and plasma samples versus tumour tissue for detection of EGFR mutation in
507 patients with advanced non-small cell lung cancer: comparison of methodologies. *J Clin*
508 *Pathol*. 2013 Dec 1;66(12):1065–9.
- 509 28. Porcel JM. Biomarkers in the diagnosis of pleural diseases: a 2018 update. *Ther Adv Respir*
510 *Dis*. 2018 Dec;12:1753466618808660.
- 511 29. Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, Rodríguez-Panadero F. Use of a panel
512 of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-
513 3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and
514 malignant effusions. *Chest*. 2004 Dec;126(6):1757–63.

- 515 30. Porcel JM, Civit C, Esquerda A, Salud A, Bielsa S. Utility of CEA and CA 15-3
516 measurements in non-purulent pleural exudates in the diagnosis of malignancy: A single-
517 center experience. *Arch Bronconeumol*. 2017 Aug;53(8):427–31.
- 518 31. Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJO, et al. Clinical
519 impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. *Am J*
520 *Respir Crit Care Med*. 2009 Sep 1;180(5):437–44.
- 521 32. Tamiya M, Tamiya A, Yasue T, Nakao K, Omachi N, Shiroyama T, et al. Vascular
522 Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome
523 After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer
524 with Malignant Pleural Effusion. *Anticancer Res*. 2016 Jun;36(6):2939–44.
- 525 33. Fiorelli A, Vicidomini G, Di Domenico M, Napolitano F, Messina G, Morgillo F, et al.
526 Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and
527 malignant origin and its clinical applications. *Interact Cardiovasc Thorac Surg*. 2011
528 Mar;12(3):420–4.
- 529 34. Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the
530 evaluation of pleural effusion: analysis of 414 cases. *Mayo Clin Proc*. 1985 Mar;60(3):158–
531 64.
- 532 35. Nance KV, Shermer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared
533 with that of pleural fluid examination. *Mod Pathol*. 1991 May;4(3):320–4.
- 534 36. Attanoos RL, Gibbs AR. The comparative accuracy of different pleural biopsy techniques
535 in the diagnosis of malignant mesothelioma. *Histopathology*. 2008 Sep;53(3):340–4.
- 536 37. McLaughlin KM, Kerr KM, Currie GP. Closed pleural biopsy to diagnose mesothelioma:
537 dead or alive? *Lung Cancer*. 2009 Sep;65(3):388–9.
- 538 38. Paintal A, Raparia K, Zakowski MF, Nayar R. The diagnosis of malignant mesothelioma in
539 effusion cytology: a reappraisal and results of a multi-institution survey. *Cancer*
540 *Cytopathol*. 2013 Dec;121(12):703–7.
- 541 39. Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant
542 pleural effusion. *Thorax*. 2009 Feb;64(2):139–43.
- 543 40. Koegelenberg CFN, Irusen EM, von Groote-Bidlingmaier F, Bruwer JW, Batubara EMA,
544 Diacon AH. The utility of ultrasound-guided thoracentesis and pleural biopsy in
545 undiagnosed pleural exudates. *Thorax*. 2015 Oct;70(10):995–7.
- 546 41. Maskell NA, Gleeson FV, Davies RJO. Standard pleural biopsy versus CT-guided cutting-
547 needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised
548 controlled trial. *Lancet*. 2003 Apr 19;361(9366):1326–30.
- 549 42. Metintas M, Yildirim H, Kaya T, Ak G, Dundar E, Ozkan R, et al. CT Scan-Guided
550 Abrams' Needle Pleural Biopsy versus Ultrasound-Assisted Cutting Needle Pleural Biopsy

551 for Diagnosis in Patients with Pleural Effusion: A Randomized, Controlled Trial.
552 Respiration. 2016;91(2):156–63.

553 43. Hallifax RJ, Corcoran JP, Ahmed A, Nagendran M, Rostom H, Hassan N, et al. Physician-
554 based ultrasound-guided biopsy for diagnosing pleural disease. Chest. 2014
555 Oct;146(4):1001–6.

556 44. DePew ZS, Wigle D, Mullon JJ, Nichols FC, Deschamps C, Maldonado F. Feasibility and
557 Safety of Outpatient Medical Thoracoscopy at a Large Tertiary Medical Center: A
558 Collaborative Medical-Surgical Initiative. Chest. 2014 Aug 1;146(2):398–405.

559 45. Murthy V, Bessich JL. Medical thoracoscopy and its evolving role in the diagnosis and
560 treatment of pleural disease. J Thorac Dis. 2017 Sep;9(Suppl 10):S1011–21.

561 46. Rahman NM, Ali NJ, Brown G, Chapman SJ, Davies RJO, Downer NJ, et al. Local
562 anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010. Thorax.
563 2010 Aug;65 Suppl 2:ii54–60.

564 47. Rozman A, Camlek L, Marc Malovrh M, Kern I, Schönfeld N. Feasibility and safety of
565 parietal pleural cryobiopsy during semi-rigid thoracoscopy. Clin Respir J. 2016
566 Sep;10(5):574–8.

567 48. Dhooria S, Singh N, Aggarwal AN, Gupta D, Agarwal R. A randomized trial comparing the
568 diagnostic yield of rigid and semirigid thoracoscopy in undiagnosed pleural effusions.
569 Respir Care. 2014 May;59(5):756–64.

570 49. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of
571 188 consecutive patients. Part 1: Diagnosis. Cancer. 1993 Jul 15;72(2):389–93.

572 50. Metintas M, Ak G, Dundar E, Yildirim H, Ozkan R, Kurt E, et al. Medical thoracoscopy vs
573 CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural
574 effusions: a randomized, controlled trial. Chest. 2010 Jun;137(6):1362–8.

575 51. Harris RJ, Kavuru MS, Mehta AC, Medendorp SV, Wiedemann HP, Kirby TJ, et al. The
576 impact of thoracoscopy on the management of pleural disease. Chest. 1995
577 Mar;107(3):845–52.

578 52. de Groot M, Walther G. Thoracoscopy in undiagnosed pleural effusions. S Afr Med J. 1998
579 Jun;88(6):706–11.

580 53. McDonald CM, Pierre C, de Perrot M, Darling G, Cypel M, Pierre A, et al. Efficacy and
581 Cost of Awake Thoracoscopy and Video-Assisted Thoracoscopic Surgery in the
582 Undiagnosed Pleural Effusion. Ann Thorac Surg. 2018 Aug 1;106(2):361–7.

583 54. Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and
584 quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral
585 thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol. 2016
586 Jun;17(6):836–44.

- 587 55. Davies HE, Nicholson JE, Rahman NM, Wilkinson EM, Davies RJO, Lee YCG. Outcome
588 of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. *Eur J*
589 *Cardiothorac Surg*. 2010 Oct;38(4):472–7.
- 590 56. Patil CB, Dixit R, Gupta R, Gupta N, Indushekar V. Thoracoscopic evaluation of 129 cases
591 having undiagnosed exudative pleural effusions. *Lung India*. 2016 Oct;33(5):502–6.
- 592 57. Vakil E, Ost D, Vial MR, Stewart J, Sarkiss MG, Morice RC, et al. Non-specific pleuritis in
593 patients with active malignancy. *Respirology*. 2018;23(2):213–9.
- 594 58. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the
595 management of cancer. *Nat Rev Clin Oncol*. 2017 Sep;14(9):531–48.
- 596 59. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al.
597 Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. *Nature*.
598 2017;545(7655):446.
- 599 60. Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky DJ, et al.
600 Detection of cancer DNA in plasma of patients with early-stage breast cancer. *Clin Cancer*
601 *Res*. 2014 May 15;20(10):2643–50.
- 602 61. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA
603 analysis detects minimal residual disease and predicts recurrence in patients with stage II
604 colon cancer. *Sci Transl Med*. 2016 06;8(346):346ra92.
- 605 62. Karlovich C, Goldman JW, Sun J-M, Mann E, Sequist LV, Konopa K, et al. Assessment of
606 EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase
607 I study of rociletinib (CO-1686). *Clin Cancer Res*. 2016;22(10):2386–2395.
- 608 63. Tang Y, Wang Z, Li Z, Kim J, Deng Y, Li Y, et al. High-throughput screening of rare
609 metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer
610 patients. *Proc Natl Acad Sci*. 2017;114(10):2544–2549.
- 611 64. Psallidas I, Kanellakis NI, Gerry S, Thézénas ML, Charles PD, Samsonova A, et al.
612 Development and validation of response markers to predict survival and pleurodesis
613 success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.
614 *Lancet Oncol*. 2018;19(7):930–939.
- 615 65. de Fonseka D, Underwood W, Stadon L, Rahman N, Edey A, Rogers C, et al. Randomised
616 controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-
617 CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural
618 malignancy (TARGET trial). *BMJ Open Respir Res*. 2018;5(1):e000270.
- 619 66. Zhou H, Zhang J, Guo L, Nie J, Zhu C, Ma X. The value of narrow band imaging in
620 diagnosis of head and neck cancer: a meta-analysis. *Sci Rep*. 2018 11;8(1):515.

- 621 67. Ishida A, Ishikawa F, Nakamura M, Miyazu YM, Mineshita M, Kurimoto N, et al. Narrow
622 band imaging applied to pleuroscopy for the assessment of vascular patterns of the pleura.
623 *Respir Int Rev Thorac Dis.* 2009;78(4):432–9.
- 624 68. Wang J, Zhou D, Xie X, Shen P, Zeng Y. Utility of contrast-enhanced ultrasound with
625 SonoVue in biopsy of small subpleural nodules. *Int J Clin Exp Med.* 2015;8(9):15991–8.

626

627

628

629

630 **FIGURE LEGENDS:**

631 **Figure 1:** Colors correspond to the three modalities capable of definitively establishing the
632 presence of pleural malignancy: green – pleural fluid cytology, red – needle biopsy of the pleura,
633 blue- thoracoscopy.

634 **In light of challenges posed by small specimens for the confident diagnosis and histological
635 subtyping of mesothelioma, acquisition of thoracoscopic tissue biopsies is preferred when such
636 sampling is permitted by local availability and expertise.

637 MPE = Malignant Pleural Effusion

638

639 **Figure 2:** ¹⁸FDG-PET/CT fusion image demonstrating diffusely increased ¹⁸FDG uptake in the
640 pleural membranes of the left hemithorax (SUV_{max} 6.84). Needle biopsy of the pleura showed
641 squamous cell carcinoma.

642

643 **Figure 3:** Still image captured during cutting needle (CN) biopsy of pleural thickening (PT). The
644 tip of the needle (CN tip) is located in the accompanying pleural fluid (PF).

Figure 4: An image acquired during medical thoracoscopy showing diffuse nodularity of the parietal pleura, a pattern consistent with metastatic pleural malignancy.

Table 1: Summary of representative performance characteristics of diagnostic modalities for metastatic pleural malignancy discussed in the text. Only the modalities in bold are definitive because they provide cytohistological material. Data adapted from references 3, 10, 13, 16, 19, 25, 28, 29, 30, 35, 36, 44 and 46.

^aThese tumor marker thresholds for elevation intentionally correspond to 100% specificity to preclude false positivity

^bCT features directly suggestive of pleural malignancy include nodular, mediastinal, and circumferential forms of pleural thickening

^cFDG avidity assessed qualitatively by comparison to background mediastinal activity

^dIncludes data corresponding to the use of both dynamic and static imaging

ADA=Adenosine Deaminase, CA 15-3=Cancer Antigen 15-3, CEA=Carcinoembryonic Antigen, CT=Computed Tomography, ¹⁸FDG-PET=¹⁸Fluorodeoxyglucose Positron Emission Tomography, LDH=Lactate Dehydrogenase, PF=Pleural Fluid, US=Ultrasound, VEGF=Vascular Endothelial Growth Factor

Diagnostic Modality	Sensitivity	Specificity
Serum LDH/PF ADA ratio > 20	98%	94%

PF CEA >45ng/ml or CA15-3>77IU/ml^a	60%	100%
PF VEGF >652pg/ml	63%	83%
Chest CT^b	68%	78%
¹⁸FDG-PET/CT^c	93%	93%
PF Cytology	46%-59%	100%
Blind Needle Pleural Biopsy	43%-45%	100%
Pleural Needle Biopsy aided by US^d	61%-90%	100%
Pleural Needle Biopsy aided by CT^d	77%-87%	100%
Medical/Surgical Thoracoscopy	89%- 95%	100%